DOCSLIB.ORG

Immuno-Oncology IO

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Immuno-Oncology IO AUGUST 29-SEPTEMBER 2, 2016 Cover MARRIOTT LONG WHARF CAMBRIDGE HEALTHTECH INSTITUTE’S 4TH ANNUAL BOSTON, MA Conference- at-a-Glance IO Immuno-Oncology SUMMIT Collaborating to Develop the Next Generation of Targeted Immunotherapy Keynotes REGISTER BY JULY 29 AND SAVE UP TO $200! Faculty Short Courses Sponsor & Exhibit Opportunities Conference Programs Plenary Keynote Speakers Training Seminar Immunomodulatory Combination Adoptive T Cell Antibodies Immunotherapy Therapy Agenda Oncolytic Virus Personalized Biomarkers Immunotherapy Immunotherapy for Immuno-Oncology Edward Michael Morganna Hotel & Travel Fritsch Rosenzweig Freeman Information Ph.D., Chief Ph.D., Executive D.O., Associate Director, Training Seminar: Preclinical & Clinical Trials Technology Director, Biology- Melanoma & Cutaneous Ts Immunology for Drug Translational for Cancer Officer, Neon Discovery, IMR Early Oncology Program, Discovery Scientists Immuno-Oncology Immunotherapy Therapeutics, Inc Discovery, Merck Re- The Angeles Clinic and Registration search Laboratories Research Institute Information CORPORATE SPONSORS CORPORATE SUPPORT SPONSORS Click Here to Register Online! Immuno-Oncology Summit.com 250 First Avenue Needham, MA 02494 www.healthtech.com Cover IO Immuno-Oncology SUMMIT Conference- at-a-Glance MEET THOUGHT LEADERS IN CANCER IMMUNOTHERAPY AT THE PREMIER ANNUAL IO EVENT As our understanding of tumor immunology combinations through clinical development and Who Will Attend? Keynotes has advanced, immuno-oncology has made into the market. This weeklong, nine-meeting set Scientific leaders, C-level executives, professors, unprecedented progress in improving the will include topics ranging from early discovery site directors and researchers from pharma, outcomes for cancer patients. Still, with the field through clinical development as well as emerging biotech, academia, and government working in Faculty in its infancy, the full curative potential of IO has areas such as oncolytic virus immunotherapy. the areas of immuno-oncology, immunotherapy, yet to be realized. CHI’s 4th Annual Immuno- Overall, this event will provide a focused look antibody and protein engineering, biomarker Oncology Summit has been designed to support at how researchers are applying new science discovery, immunology, cell and gene therapy, a coordinated effort by industry players to bring and technology in the development of the next and preclinical and clinical development. Short Courses commercial immunotherapies and immunotherapy generation of effective and safe immunotherapies. Sponsor & Exhibit CONFERENCE AT-A-GLANCE Opportunities MONDAY TUESDAY WEDNESDAY THURSDAY FRIDAY Training Seminar Agenda Immunomodulatory Combination Adoptive T Cell Hotel & Travel Antibodies Immunotherapy Therapy Information Registration Information Oncolytic Virus Personalized Biomarkers for Click Here to Immunotherapy Immunotherapy Immuno-Oncology Register Online! Immuno-Oncology Summit.com Training Seminar: Preclinical & Clinical Trials Immunology for Drug Translational for Cancer Discovery Scientists Immuno-Oncology Immunotherapy 250 First Avenue Needham, MA 02494 www.healthtech.com Cover Plenary Keynotes TUESDAY | AUGUST 30 Conference- at-a-Glance Keynotes 4:00 Personalized, Neoantigen- 4:30 Emerging Innate Immune Targets for 5:00 Reading Tea Leaves: The Dilemma of Based Immunotherapy Enhancing Adaptive Anti-Tumor Responses Prediction and Prognosis in Immunotherapy Faculty Edward Fritsch, Ph.D., Chief Technology Michael Rosenzweig, Ph.D., Executive Morganna Freeman, D.O., Associate Director, Officer, Neon Therapeutics, Inc. Director, Biology-Discovery, IMR Early Melanoma & Cutaneous Oncology Program, Multiple lines of evidence have demonstrated the Discovery, Merck Research Laboratories The Angeles Clinic and Research Institute Short Courses critical role that Neoantigens have in the im- Novel cancer immunotherapies targeting T cell With the rapid expansion of immunotherapeutics mune response to cancer and the availability of checkpoint proteins have emerged as powerful tools in oncology, scientifically significant advances next-generation sequencing to identify personal, to induce profound, durable regression and remission have been made with both the depth and duration neoantigen-creating mutations has opened the of many types of cancer. Despite these advances, mul- of antitumor responses. However, not all patients Sponsor & Exhibit door to directly enhance the power and breadth of tiple studies have demonstrated that not all patients benefit, or quickly relapse, thus much scientific Opportunities host immunity to overcome this deadly disease. respond to these therapies, and the ability to predict inquiry has been devoted to appropriate patient se- which patients may respond is limited. Harnessing the lection and how such obstacles might be overcome. innate immune system to augment the adaptive anti-tu- While more is known about potential biomarkers, mor response represents an attractive target for ther- accurate prognostication persists as a knowledge Training Seminar apy, which has the potential to enhance both the per- gap, and efforts to bridge it will be discussed here. centage and rate of response to checkpoint blockade. Agenda Jakob Dupont, M.D., Senior David M. Kranz, Track Keynotes Vice President & CMO, Ph.D., Phillip A. Sharp Hotel & Travel OncoMed Pharmaceuticals Professor of Biochemistry, University of Illinois Information Prasad S. Adusumuilli, Kenneth Emancipator, Laszlo Radvanyi, Ph.D., M.D., FACS, Deputy Chief of M.D., Executive Medical Senior Vice President and Head, Registration Translational & Clinical Research, Director, Companion ImmunoOncology Translational Information Thoracic Surgery, Memorial Diagnostics, Merck & Co. Innovation Platform (TIP) EMD Serono Sloan-Kettering Cancer Center Roy D. Baynes, M.D., Ronald Herbst, Ph.D., Vice Zhen Su, M.D., MBA, Senior Click Here to Ph.D., Senior Vice President President, R&D; Head, Oncology Vice President, Global Register Online! and Head, Global Clinical Research, MedImmune Head of Medical Affairs Development, Merck Oncology, EMD Serono Immuno-Oncology Research Laboratories Summit.com Edward Cha, M.D., Ph.D., Robert Iannone, M.D., Senior James E. Wooldridge, Associate Medical Director, Vice President & Head, Immuno- M.D., CSO, Immuno-Oncology Cancer Immunotherapy Oncology, Global Medicines Clinical Development, Franchise, Genentech Development, AstraZeneca Eli Lilly and Company Robert Coffin, Ph.D., Ella Ioffe, Ph.D., Associate CEO, Replimmune Director, Immune-Oncology, 250 First Avenue Regeneron Pharmaceuticals Needham, MA 02494 www.healthtech.com Cover Join the conversation! Conference- at-a-Glance IOSUMMIT Keynotes Faculty Short Courses Sponsor & Exhibit Opportunities Training Seminar Agenda Distinguished Faculty Hotel & Travel Information Adam J. Adler Roy D. Baynes Chris Boshoff Manel Cascallo Yeong “Christopher” Choi Anthony Davies Boris Engels Ph.D., Professor, M.D., Ph.D., Senior Vice M.D., Ph.D., Vice President Ph.D., Co-Founder, Ph.D., Director, TCPF Ph.D., COO, 4D Molecular Ph.D., Investigator, Immunology, University President and Head, Global and Head, Early, Develop- President and CEO, and Assistant Professor Therapeutics Exploratory Immuno-On- Registration of Connecticut Clinical Development, Mer- ment, Translational and VCN Biosciences of Oncology, Center for John Desjarlais cology, Novartis Institutes ck Research Laboratories Immuno-Oncology, Pfizer Immunotherapy, Roswell Information Prasad S. Adusumilli Saso Cemerski Ph.D., CSO, Xencor for Biomedical Research M.D., FACS, Deputy Chief of Stephen Beers Adrian Bot Ph.D., Associate Park Cancer Institute Luis Alberto Diaz Andrew M. Evens Translational & Clinical, Re- Ph.D., Associate Professor, M.D., Ph.D., Vice President, Principal Scientist, Merck Robert Coffin M.D., Associate Professor, D.O., Professor and Chief, search, Thoracic Surgery, Cancer Immunology and Translational Sciences, Research Laboratories Ph.D., CEO, Replimmune Oncology, Johns Hopkins Hematology/Oncology, Memorial Sloan-Kettering Immunotherapy, University R&D, Kite Pharma Inc. Edward Cha Joe Conner Sidney Kimmel Comprehen- Tufts University School Cancer Center of Southampton Click Here to Caroline Breitbach M.D., Ph.D., Associate Ph.D., CSO, Virttu Biologics sive Cancer Center of Medicine; Director, Omar Ali John Bell Ph.D., Vice President, Medical Director, Tufts Cancer Center Register Online! Michael A. Curran Gianpietro Dotti Ph.D., Staff Scientist, Wyss Ph.D., Senior Scientist, Translational Development, Cancer Immunotherapy Ph.D., Assistant Professor, M.D., Professor, Microbi- Christopher R. Heery Institute for Biologically Centre for Innovative Turnstone Biologics Franchise, Genentech Immuno-Oncology Immunology; Scientific Di- ology and Immunology, M.D., Director, Clinical Inspired Engineering, Cancer Research, Ottawa Summit.com Joshua Brody Brian Champion rector, ORBIT Platform MD University of North Carolina Trials Group, Laboratory of Harvard University Hospital Research Institute, M.D., Director, Lymphoma Ph.D., Senior Vice Anderson Cancer Center Tumor Immunology, Center Professor, Departments of Jakob Dupont Robert Anders Immunotherapy Program, President, R&D, PsiOxus for Cancer Research Medicine and Biochemistry, Adil Daud M.D., Senior Vice M.D., Ph.D., Associate Icahn School of Medicine Therapeutics Ltd Christian S. Hinrichs Microbiology & Immunol- M.D., Professor, Hematolo- President & CMO, OncoMed Professor, Pathology, at Mount Sinai Zhao Chen gy/Oncology, University of Pharmaceuticals
Load more

Recommended publications
  • Kate Fitzgerald
    In This Issue: 2020 Young Investigator Awardees pg. 3-9 In Memorium page pg. 14-15 New Member Mini-Bios pg. 19-21 Trials of Interferon Lambda pg. 31 Cytokines 2021 Hybrid Meetin pg. 24-27 Signals THE INTERNATIONAL CYTOKINE & INTERFERON SOCIETY + NEWSLETTER APRIL 2021 I VOLUME 9 I NO. 1 A NOTE FROM THE ICIS PRESIDENT Kate Fitzgerald Dear Colleagues, Greetings from the International Cytokine and Interferon Society! I hope you and your family are staying safe during these still challenging times. Thankfully 2020 is behind us now. We have lived through the COVID-19 pandemic, an event that will continue to impact our lives for some time and likely alter how we live in the future. Despite the obvious difficulties of this past year, I can’t help but marvel at the scientific advances that have been made. With everything from COVID-19 testing, to treatments and especially to the rapid pace of vaccine development, we are so better off today than even a few months back. The approval of remarkably effective COVID-19 vaccines now rolling out in the US, Israel, UK, Europe and across the globe, brings light at the end of the tunnel. The work of many of you has helped shape our understanding of the host response to Sars-CoV2 and the ability of this virus to limit antiviral immunity while simultaneously driving a cytokine driven hyperinflammatory response leading to deadly consequences for patients. The knowledge gained from all of your efforts has been put to good use to stem the threat of this deadly virus.
    [Show full text]
  • WO 2016/106159 Al 30 June 2016 (30.06.2016) W P O P C T
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2016/106159 Al 30 June 2016 (30.06.2016) W P O P C T (51) International Patent Classification: (74) Agents: BALICKY, Eric, M. et al; Hamilton, Brook, C07K 16/28 (2006.01) Smith & Reynolds, P.C., 530 Virginia Rd, P.O. Box 9133, Concord, MA 01742-9133 (US). (21) International Application Number: PCT/US20 15/066954 (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, (22) Date: International Filing AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, 19 December 2015 (19. 12.2015) BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, (25) Filing Language: English DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, (26) Publication Language: English KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, (30) Priority Data: MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, 62/095,675 22 December 2014 (22. 12.2014) US PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, 62/220,199 17 September 2015 (17.09.2015) US SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, 62/25 1,082 4 November 2015 (04. 11.2015) US TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
    [Show full text]
  • Hemispherx Biopharma, Inc
    Hemispherx Biopharma, Inc. HEB‐NYSE EXECUTIVE INFORMATIONAL OVERVIEW® November 27, 2016 Company Description Hemispherx Biopharma, Inc. (or “the Company”) is a specialty pharmaceutical company addressing critical unmet medical needs. The Company has invested over two decades of R&D into safe, effective ways to modulate and amplify the immune system, and is now poised to enter a confirmatory Phase III U.S. trial with an RNA† Hemispherx Biopharma, Inc. macromolecule that could become the only FDA‐approved therapy 1617 JFK Blvd., Suite 500 for chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME). Philadelphia, PA 19103 This candidate, Ampligen®, was approved for CFS/ME in Argentina in Phone: (215) 988‐0080 August 2016 and is available to patients in Europe through an early access program (EAP). CFS/ME is a debilitating disease with no Fax: (215) 988‐1739 www.hemispherx.net/ known treatment to date but very active patient advocacy groups. Hemispherx also holds rights to an FDA‐approved product for genital warts, Alferon N Injection®, which is believed to be the world’s only Ticker (Exchange) HEB (NYSE) approved natural interferon (IFN). Hemispherx has refined Alferon’s Recent Price (11/25/2016)* $0.85 manufacturing to drastically increase efficiencies and reduce costs, and now seeks FDA approval for the new production method before 52‐week Range $0.72 ‐ $2.64 relaunching Alferon. Hemispherx is headquartered in Philadelphia Shares Outstanding** ~24.1 million with GMP manufacturing and research facilities in New Jersey. Market Capitalization ~$20.5 million Average 3‐month Volume 110,574 Key Points Insider Ownership ~3.6 million The Ampligen® technology has also shown utility as a broad‐ Institutional Ownership ~5% spectrum antiviral that could help seasonal flu vaccines work EPS (Qtr.
    [Show full text]
  • COVID-19 Treatment and Vaccine Tracker This Document Contains an Aggregation of Publicly Available Information from Validated Sources
    COVID-19 Treatment and Vaccine Tracker This document contains an aggregation of publicly available information from validated sources. It is not an endorsement of one approach or treatment over another but simply a list of all treatments and vaccines currently in development. TREATMENTS Current Type of FDA-Approved Clinical Trials for Funding Clinical Trials for Anticipated Next Number Developer/Researcher Stage of Published Results Sources Product - Treatment Indications Other Diseases Sources COVID-19 Steps Timing Development ANTIBODIES PhRMA Begin Phase 1 trials in late Polyclonal hyperimmune Alliance among Takeda, CSL Behring, Wall Street Journal spring. To patients between 1 globulin (H-IG), formerly N/A Biotest AG, Bio Products Laboratory, Pre-clinical Pink Sheet December 2020 and December known at TAK-888 LFB, and Octapharma Press release from the 2021 alliance Biomedical Stat News Advanced MarketWatch Antibodies from mice, Research and Reuters 2 REGN3048-3051, against the N/A Regeneron Pre-clinical Start Phase 1 June 2020 Development Bloomberg News spike protein Authority FierceBiotech (BARDA) FiercePharma Korea Herald Antibodies from recovered 3 N/A Celltrion Pre-clinical Start Phase 1 in July 2020 UPI COVID-19 patients Celltrion press release Super-antibody or antibody 4 cocktail to target potential N/A Celltrion Pre-clinical Celltrion press release mutations of SARS-CoV-2 Antibodies from recovered BioSpace 5 N/A Kamada Pre-clinical COVID-19 patients AbbVie Stat News Antibodies from recovered 6 N/A Vir Biotech/WuXi Biologics/Biogen Pre-clinical Start Phase 1 ~ July 2020 Vir Biotech COVID-19 patients Vir Biotech * Indicates updated or new field This document contains an aggregation of publicly available information from validated sources.
    [Show full text]
  • Public Summary of Opinion on Orphan Designation Rintatolimod for the Treatment of Ebola Virus Disease
    19 May 2015 EMA/COMP/204227/2015 Committee for Orphan Medicinal Products Public summary of opinion on orphan designation Rintatolimod for the treatment of Ebola virus disease On 24 April 2015, orphan designation (EU/3/15/1480) was granted by the European Commission to NV Hemispherx BioPharma Europe, Belgium, for rintatolimod for the treatment of Ebola virus disease. What is Ebola virus disease? Ebola virus disease is a severe disease caused by infection with viruses known as ebolaviruses. There are 5 known species of ebolavirus, 4 of which are known to cause the disease in humans. Zaire ebolavirus, sometimes referred to simply as ‘ebola virus’ or EBOV, is the cause of the largest outbreaks of the disease to date and has led to the most deaths. Infection is caused by contact with the body fluids of an infected person. After infection there is an incubation period of between 2 to 21 days, following which the newly infected person starts to experience symptoms. The first symptoms typically are fever, headache, fatigue, muscle pain and sore throat. These are followed by other symptoms such as diarrhoea, vomiting, rash, kidney and liver problems and, in some cases, internal bleeding and bleeding from the gums, eyes, nose and ears. Patients are infectious once they start experiencing symptoms. Ebola virus disease is a life-threatening condition that is frequently fatal due to fluid loss and severe bleeding. What is the estimated number of patients affected by the condition? At the time of designation, Ebola virus disease affected less than 0.01 in 10,000 people in the European Union (EU).
    [Show full text]
  • Overview of Planned Or Ongoing Studies of Drugs for the Treatment of COVID-19
    Version of 16.06.2020 Overview of planned or ongoing studies of drugs for the treatment of COVID-19 Table of contents Antiviral drugs ............................................................................................................................................................. 4 Remdesivir ......................................................................................................................................................... 4 Lopinavir + Ritonavir (Kaletra) ........................................................................................................................... 7 Favipiravir (Avigan) .......................................................................................................................................... 14 Darunavir + cobicistat or ritonavir ................................................................................................................... 18 Umifenovir (Arbidol) ........................................................................................................................................ 19 Other antiviral drugs ........................................................................................................................................ 20 Antineoplastic and immunomodulating agents ....................................................................................................... 24 Convalescent Plasma ...........................................................................................................................................
    [Show full text]
  • Immune Responses Elicited by Live Attenuated Influenza Vaccines As
    Review Immune Responses Elicited by Live Attenuated Influenza Vaccines as Correlates of Universal Protection against Influenza Viruses Yo Han Jang 1,2 and Baik L. Seong 3,4,* 1 Department of Biological Sciences and Biotechnology Major in Bio-Vaccine Engineering, Andong National University, Andong 1375, Korea; [email protected] 2 Vaccine Industry Research Institute, Andong National University, Andong 1375, Korea 3 Department of Biotechnology, College of Life Science and Biotechnology, Yonsei University, Seoul 03722, Korea 4 Vaccine Innovation Technology Alliance (VITAL)-Korea, Yonsei University, Seoul 03722, Korea * Correspondence: [email protected]; Tel.: +82-2-2123-7416 Abstract: Influenza virus infection remains a major public health challenge, causing significant mor- bidity and mortality by annual epidemics and intermittent pandemics. Although current seasonal influenza vaccines provide efficient protection, antigenic changes of the viruses often significantly compromise the protection efficacy of vaccines, rendering most populations vulnerable to the viral infection. Considerable efforts have been made to develop a universal influenza vaccine (UIV) able to confer long-lasting and broad protection. Recent studies have characterized multiple immune correlates required for providing broad protection against influenza viruses, including neutralizing antibodies, non-neutralizing antibodies, antibody effector functions, T cell responses, and mucosal immunity. To induce broadly protective immune responses by vaccination, various strategies using Citation: Jang, Y.H.; Seong, B.L. Immune Responses Elicited by Live live attenuated influenza vaccines (LAIVs) and novel vaccine platforms are under investigation. Attenuated Influenza Vaccines as Despite superior cross-protection ability, very little attention has been paid to LAIVs for the develop- Correlates of Universal Protection ment of UIV.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2016/0319019 A1 Amirina Et Al
    US 201603.19019A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2016/0319019 A1 Amirina et al. (43) Pub. Date: Nov. 3, 2016 (54) ANTI-PD-1 ANTIBODIES (22) Filed: May 11, 2016 (71) Applicant: Enumeral Biomedical Holdings, Inc., Related U.S. Application Data Cambridge, MA (US) (62) Division of application No. 14/975,769, filed on Dec. 19, 2015. (72) Inventors: Najmia Amirina, Cambridge, MA (60) Provisional application No. 62/095.675, filed on Dec. (US); Hareesh Chamarthi, Allston, 22, 2014, provisional application No. 62/220,199, MA (US); Maria Isabel Chiu, Newton filed on Sep. 17, 2015, provisional application No. Centre, MA (US); Daniel Doty, 62/251,082, filed on Nov. 4, 2015, provisional appli Arlington, MA (US); Bin Feng, cation No. 62/261,118, filed on Nov. 30, 2015. Newton, MA (US); Aleksander Jonca, Publication Classification Boston, MA (US); Thomas McQuade, Cambridge, MA (US); Anhco Nguyen, (51) Int. Cl. Needham, MA (US); Sheila C07K 6/28 (2006.01) Ranganath, Arlington, MA (US); Hans (52) U.S. Cl. Albert Felix Scheuplein, Arlington, CPC ..... C07K 16/2803 (2013.01); C07K 231 7/567 MA (US); Vikki A. Spaulding, Acton, (2013.01); C07K 23.17/34 (2013.01); A61 K MA (US); Lei Wang, Braintree, MA 2039/507 (2013.01) (US); Jennifer Watkins-Yoon, Brighton, MA (US) (57) ABSTRACT Antibodies that bind to programmed cell death protein 1 (PD-1), compositions comprising Such antibodies, and (21) Appl. No.:y x- - - 15/152,1929 methods of making and using Such antibodies are disclosed. Patent Application Publication Nov. 3, 2016 Sheet 3 of 27 US 2016/0319019 A1 s's is 5 w c.
    [Show full text]
  • 2018 Medicines in Development for Cancer
    2018 Medicines in Development for Cancer Bladder Cancer Product Name Sponsor Indication Development Phase ABI-009 AADi Bioscience non-muscle invasive bladder cancer Phase I/II (nab-rapamycin/mTOR inhibitor) Los Angeles, CA www.aadibio.com ALT-801 Altor BioScience non-muscle invasive bladder cancer Phase I/II (tumor antigen-specific T-cell Miramar, FL www.altorbioscience.com receptor linked to IL-2) NantKwest Culver City, CA ALT-803 Altor BioScience non-muscle invasive bladder cancer Phase II (IL-15 superagonist protein complex) Miramar, FL (BCG naïve) (Fast Track), www.altorbioscience.com NantKwest non-muscle invasive bladder cancer Culver City, CA (BCG unresponsive) (Fast Track) B-701 BioClin Therapeutics 2L locally advanced or metastatic Phase I/II (anti-FGFR3 mAb) San Ramon, CA bladder cancer www.bioclintherapeutics.com Bavencio® EMD Serono 1L urothelial cancer Phase III avelumab Rockland, MA www.emdserono.com (anti-PD-L1 inhibitor) Pfizer www.pfizer.com New York, NY BC-819 BioCanCell Therapeutics non-muscle invasive bladder cancer Phase II (gene therapy) Cambridge, MA (Fast Track) www.biocancell.com Medicines in Development: Cancer ǀ 2018 1 Bladder Cancer Product Name Sponsor Indication Development Phase Capzola® Spectrum Pharmaceuticals non-muscle invasive bladder cancer application submitted apaziquone Henderson, NV (Fast Track) www.sppirx.com Cavatak® Viralytics bladder cancer (+pembrolizumab) Phase I coxsackievirus Sydney, Australia www.viralytics.com CG0070 Cold Genesys non-muscle invasive bladder cancer Phase II (oncolytic immunotherapy)
    [Show full text]
  • Local and Regional Therapy for Primary and Locally Recurrent Melanoma
    Local and Regional Therapy for Primary and Locally Recurrent Melanoma Justin G. Wilkes, MD,1,2 Ayushi Patel, BS,2 and Jonathan S. Zager, MD1,2 1Department of Cutaneous Oncology, Moffitt Cancer Center, Tampa, Florida 2University of South Florida Morsani College of Medicine, Tampa, Florida Corresponding author: Abstract: In the vast majority of cases, cutaneous melanoma Jonathan S. Zager, MD pre sents as localized disease and is treated with wide excision and Moffitt Cancer Center sentinel lymph node biopsy, with shared decision making regard- 10920 North McKinley Drive ing completion lymph node dissection and adjuvant systemic Room 4.4123 Tampa, FL 33612 therapy. The treatment of recurrent and in-transit disease is more Tel: (813) 745-1085 complex, with further options for regional and systemic therapies Fax: (813) 745-5725 and multiple variables to be factored into decisions. Rates of over- Email: [email protected] all and complete response to regional therapies can be quite high in carefully chosen patients, which limits the need for systemic therapies and their inherent side effects. Ongoing trials aim to assess the efficacy of combination regional and systemic therapies and assist in deciding among these options. This review discusses the treatment of primary melanoma and regional nodal disease and offers an in-depth discussion of options for the treatment of recurrent melanoma and in-transit melanoma. Introduction Melanoma is the fifth most common cancer in the United States and the 17th-leading cause of cancer-related death, with recent declines in mortality following US Food and Drug Administration (FDA) approval of immunotherapy and targeted therapy agents.1 Newly diagnosed melanoma most commonly presents as primary disease, accounting for 84% of patients.
    [Show full text]
  • Adjuvanted Corn Nanoparticle Enhances the Breadth of Inactivated
    Poly(I:C) adjuvanted corn nanoparticle enhances the breadth of inactivated influenza virus vaccine immune response in pigs Thesis Presented in Partial Fulfillment of the Requirements for the Degree Master of Science in the Graduate School of The Ohio State University By Ninoshkaly Feliciano Ruiz, B.S. BiomedSc Graduate Program in Comparative and Veterinary Medicine The Ohio State University 2020 Thesis Committee Dr. Renukaradhya J. Gourapura, Advisor Dr. Feng Qu Dr. Scott P. Kenney 1 Copyrighted by Ninoshkaly Feliciano Ruiz 2020 2 Abstract Influenza A virus (IAV) is known for causing respiratory viral infections in a broad spectrum of birds and mammals, including humans and pigs. Pig acts as a mixing vessel for the generation of new reassortant IAV viruses of pandemic potential, like the 2009 H1N1 virus strain. The most common method to control of IAV in farms is by the intramuscular (IM) immunization of pig with killed multivalent IAV vaccine. However, IM immunization induces poor mucosal secretory IgA (SIgA) antibody response in the airways and thus confers highly variable levels of protection. Intranasal (IN) immunization studies using nanoparticle-based IAV vaccines in pigs have shown to increase the specific mucosal SIgA antibody response, cell-mediated immune response and enhances the production of pro-inflammatory cytokines. In this study, we overview the pig immune system to fight IAV infections, different vaccination strategies and several adjuvants that have been tested in pig against swine influenza. Recently, we develop and characterized a sweet corn-derived cationic alpha-D-glucan nanoparticle (Nano-11) and established its adjuvant potential in mice and pigs.
    [Show full text]
  • Developing a Novel Concept Regenerative Treatment for DPN: Engensis (VM202) Phase 3 Results and Future Plans
    Developing a Novel Concept Regenerative Treatment for DPN: Engensis (VM202) Phase 3 Results and Future Plans Seung Shin Yu Disclosure Disclaimer This presentation has been prepared by Helixmith Co., Ltd. (“Company”) solely for your information and for your use and may not be taken away, distributed, reproduced, or redistributed or passed on, directly or indirectly, to any other person (whether within or outside your organization or firm) or published in whole or in part, for any purpose by recipients directly or indirectly to any other person. By accessing this presentation, you are agreeing to be bound by the trailing restrictions and to maintain absolute confidentiality regarding the information disclosed in these materials. Forward-Looking Statements This presentation may contain statements that constitute forward-looking statements. Forward-looking statements can generally by identified by the use of language such as “may”, “will”, “expect”, “estimate”, “anticipate”, “plan”, “intend”, “believe”, “potential”, “anticipate” and “continue” or the negative thereof or similar variations. These forward-looking statements are based on the current beliefs, expectations and assumptions of the Company’s management about the Company’s business, planned acquisitions, future plans, anticipated events and other future conditions. In addition, the forward- looking statements are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements, including the risks and uncertainties related to the progress, timing, cost, and result of clinical trials; difficulties or delays of regulatory filings and approvals; competition from other pharmaceutical or biotechnology companies; and our ability to obtain additional funding required to conduct our research, development, and commercialization activities, and others, all of which could cause the actual results or performance of the Company to differ materially from those contemplated in such forward-looking statements.
    [Show full text]